Factors associated with mortality among hospitalized patients with COVID-19 disease treated with convalescent plasma

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

Article Immunology

A Multicenter, Prospective, Observational, Cohort-Controlled Study of Clinical Outcomes Following Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Therapy in Hospitalized Patients With COVID-19

Lakshmi Chauhan et al.

Summary: A multicenter, prospective, cohort-controlled trial found that convalescent plasma therapy did not show benefit in time to discharge or inpatient mortality for hospitalized COVID-19 patients.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Microbiology

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes

Daniele Focosi et al.

Summary: Convalescent plasma (CP) is a frontline treatment in epidemics due to its immediate availability. The COVID-19 pandemic provided an opportunity to study the mechanisms, safety, and efficacy of CP using evidence-based medicine. However, studies have reported highly variable efficacy results for COVID-19 CP (CCP), leading to uncertainty.

CLINICAL MICROBIOLOGY REVIEWS (2022)

添加到收藏夹

Article Medicine, General & Internal

Early Outpatient Treatment for Covid-19 with Convalescent Plasma

D. J. Sullivan et al.

Summary: This study evaluated the efficacy and safety of COVID-19 convalescent plasma in symptomatic adults and found that receiving convalescent plasma transfusion reduced the risk of hospitalization due to COVID-19-related reasons.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Immunology

Adaptive Immune Responses and Immunity to SARS-CoV-2

Dragan Primorac et al.

Summary: Since the COVID-19 pandemic, the medical field has been applying immunology knowledge to understand the immune response to SARS-CoV-2. Cellular immunity has been shown to persist even years after infection, and T cells play a crucial role in both cellular and humoral immune responses. IgA production is important for mucosal immunity. Recent research has also demonstrated the long-lasting cellular immunity in those who have recovered from COVID-19 or received approved vaccines.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Predictors of mortality in COVID-19 patients treated with convalescent plasma therapy

Naomi Rahimi-Levene et al.

Summary: This study aimed to describe the survival of severe COVID-19 patients treated with convalescent COVID plasma (CCP) and identify predictors of in-hospital mortality. The study found that diabetes mellitus, mechanical ventilation, and lower albumin levels during treatment were significantly associated with increased in-hospital mortality.

PLOS ONE (2022)

添加到收藏夹

Article Pathology

Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG

Eric Salazar et al.

Summary: Convalescent plasma therapy containing high-titer anti-spike protein RBD IgG has shown to significantly reduce mortality in hospitalized COVID-19 patients when transfused within 44 hours, confirming previous findings and showing promise in the treatment of the disease.

AMERICAN JOURNAL OF PATHOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

M. J. Joyner et al.

Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal